In vitro studies on origin and site of action of enzyme activity responsible for conversion of human proapoprotein A-I into apoprotein A-I  by Kooistra, Teake et al.
Volume 170, number 1 FEBS 1418 May 1984 
In vitro studies on origin and site of action of enzyme activity 
responsible for conversion of human proapoprotein A-I into 
apoprotein A-I 
Teake Kooistra, Victor van Hinsbergh, Louis Havekes and Herman Jan Kempen 
Gaubius Institute, Health Research Division TNO, Herenstraat 5d, 2313 AD Leiden, The Netherlands 
Received 5 March 1984 
Human hepatocellular carcinoma cells (Hep G2) were shown to secrete apo A-I as a proprotein. No apo 
A-I synthesis could be detected with endothelial cells from human umbilical cord veins. Conversion of 
proapo A-I into apo A-I is a slow (of the order of hours) process, mediated by a Ca2+/Mg2+-dependent 
enzyme which is present on the surface of plasma lipoprotein particles, endothelial cells and Hep G2 cells, 
and is probably synthesized by Hep G2 cells. 
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1. INTRODUCTION 
Apo A-I is a major protein constituent of 
plasma HDL and of lymph lipoproteins in man [ 11. 
Recent studies on the biosynthesis and processing 
of apo A-I have shown that the primary translation 
product of apo A-I mRNA is a preproprotein [2] 
which undergoes intracellular co-translational pro- 
teolytic cleavage into proapo A-I. Proapo A-I is 
secreted from the cell and converted extracellularly 
into the mature form observed in plasma [2,3]. 
This conversion may be an important regulatory 
step in lipoprotein formation and a critical deter- 
minant of steady-state plasma apo A-I levels [2,3]. 
It is, therefore, of interest to characterize the en- 
zyme activity responsible for the processing of pro- 
apo A-I and its site(s) of action. For this purpose, 
radiolabelled medium of a human hepatocellular 
carcinoma cell line (Hep G2), which contains pro- 
apo A-I [2,3], was incubated with human blood, 
plasma, serum or fractions thereof, or endothelial 
cells under various experimental conditions. The 
conversion of proapo A-I into the more acidic apo 
A-I was monitored by isoelectric focusing after 
purification of the apoprotein from the medium by 
immunoprecipitation. 
2. MATERIALS AND METHODS 
Abbreviations: apo, apolipoprotein; HDL, LDL and 
VLDL, high density, low density and very low density 
lipoproteins, respectively; LPDS, lipoprotein-depleted 
serum; ECGS, endothelial cell growth supplement; 
EGF, epidermal growth factor; BSA, bovine serum 
albumin 
The established Hep G2 cell line, derived from 
human liver tumour, was obtained from Dr B.B. 
Knowles (Wistar Institute of Anatomy and 
Biology, Philadelphia, PA). Cells were grown as in 
[4]. Endothelial cells were isolated from human 
umbilical cord veins and cultured as in [5]. So that 
synthesized proteins could be labelled, confluent 
monolayers grown in 25-cm* plastic tissue culture 
flasks were washed twice with methionine-free 
RPMI-1640 medium, and incubated with 1.5 ml of 
this medium supplemented with lOO-200,&i of 
[35S]methionine/ml (300 Ci/mmol; New England 
Nuclear). With endothelial cells, the medium also 
contained 25 pg HDL and 25 pg LDL per ml. At 
the end of the incubation period, the medium was 
centrifuged for 15 min in a Beckman Microfuge 
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centrifuge to remove cells and cell debris, and 
samples were frozen at - 20°C until used. Incuba- 
tions of Hep G2 cells and endothelial cells with 
[35S]methionine were for 8 and 18 h, respectively, 
unless otherwise specified. To prepare serum-free 
conditioned medium of Hep G2 cells, confluent 
cultures were washed twice with DMEM, and in- 
cubated with DMEM, supplemented with 0.03% 
acid-treated BSA, for 48 h. Conditioned medium 
of endothelial cells was prepared in a similar way 
with Ml99 medium instead of DMEM and an in- 
cubation time of 30 h. 
Blood was obtained from healthy donors and 
collected in sterile tubes containing hirudin (Pen- 
tapharm; 300 ATUlml final cont.), heparin (Leo 
Pharm. Prod.; 10 units/m1 final cone.) or EDTA 
(0.1% final cont.) as anticoagulant. Platelet poor 
plasma was prepared by two centrifugations for 
20 min at 2000 x g and 6000 x g, respectively. 
Serum was prepared from freshly collected blood 
from the same subjects following blood clotting 
and using identical centrifugation methods. 
Density-gradient ultra~entrifugation of serum or 
radiolabelled medium from Hep C2 cells was per- 
formed as in [6]. Serum fractions were dialysed 
against RPMI-1640, and protein was measured as 
in [7]. 
For immunoprecipitation of apo A-I we used 
specific rabbit anti-human apo A-I antiserum (rais- 
ed in our laboratory) and goat anti-rabbit IgG 
(Nordic Immunology). Maximum immunoprecipi- 
tation with anti-apo A-I was achieved by adding a 
predetermined amount of cold carrier HDL. Im- 
munopre~ipitation was also performed with a 
double antibody procedure by employing rabbit 
anti-apo A-I as primary antibody and goat anti- 
rabbit IgG as second antibody. Immunoprecipi- 
tates were collected by centrifugation for 5 min in 
a Beckman microfuge, washed 3 times with ice- 
cold RPMI-1640, and dissolved in the appropriate 
electrophoresis buffer. 
SDS-PAGE was performed as in 181 with 
resolving gels of 10% acrylamide and stacking gels 
of 4% acrylamide. M, markers (Bio-Rad) were 
used for calibration of the gel. For autoradiofluo- 
rography, the gel was treated with an autoradio- 
fluorography enhancer (En3hance, New England 
Nuclear) according to the manufacturer’s instruc- 
tions, dried, and placed on X-ray film (Kodak 
X-Omat) for lo-20 days at -90°C. 
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For polyacrylamide isoelectrofocusing, im- 
munoprecipitates were mixed with 10 fig of carrier 
apo HDL (for reference), and dissolved in the lysis 
buffer used in [9]_ Electrophoresis was essentially 
as in [lo], using a 5% slab gel with a pH-gradient 
of 4-8 (2.5%, v/v, Ampholines, pH 4-6, and 
2.590, v/v, Ampholines, pH 6-8, LKB). Gels were 
prepared for autoradiofluorography as described 
above. 
Here, apo A-I isoproteins were designated as in 
131. 
3. RESULTS AND DISCUSSION 
Aliquots of [35S]methionine-labelled culture 
medium from Hep G2 and endothelial cell cultures 
were reacted with anti-apo A-I antibodies, and the 
immunopre~ipitates subjected to SDS-polyacryl- 
amide gel electrophoresis (PAGE), followed by 
autoradiography. Fig.1 shows that reaction of 
anti-apo A-I with Hep G2 medium precipitated a 
protein of h/l, 28000 that co-migrated with apo A-I 
from carrier HDL. No such protein could be 
detected with medium from endothelial cells, in- 
dicating that these cells do not secrete apo A-I or 
that secretion is below the detection limits of the 
procedure employed (O.OWo of the protein syn- 
thesized). These results suggest hat the presence of 
apo A-I in endothelial cells as observed by indirect 
immunofluorescen~e [ 1 I] is likely to be due to a 
(strong) interaction of exogenous apo A-I with 
these cells rather than to endogenous ynthesis. 
The immunoprecipitate obtained with Hep G2 
medium was further characterized by isoelectric 
focusing (fig.2). The gel stained for protein (lane a) 
shows the positions of the carrier plasma HDL 
apoproteins, and the autoradiogram (lane b) shows 
the positions of the newly synthesized [‘?S]methio- 
nine-labelled apo A-I. It can be seen that newly 
secreted apo A-I is primarily composed of iso- 
protein 2, which is more basic than the major 
plasma apo A-I isoprotein 4. This confirms the 
results in [3] where it was shown that isoprotein 2 
is the pro-form of isoprotein 4, with a 6-amino 
acid NHz-terminal extension (Arg-His-Phe-Trp- 
Gln-Gln). The two positive charges in the propep- 
tide are consistent with the two-charge difference 
observed on isoelectrofocusing of isoprotein 2 as 
compared to isoprotein 4. 
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Fig. 1. SDS-PAGE and autoradiography of 
immunoprecipitates obtained by mixing [35S]methio- 
nine-labelled culture medium from Hep G2 and endot- 
helial cells with anti-apo A-I antibodies. Lane a, 
immunoprecipitate of [35S]methionine-labelled Hep G2 
medium with rabbit anti-apo A-I as primary antibody 
and goat anti-rabbit IgG as second antibody; lane b, 
[35S]methionine-labelled Hep G2 medium mixed with 
cold carrier HDL and immunoprecipitated with rabbit 
anti-apo A-I; lane c, [35S]methionine-labelled endo- 
thelial cell medium, containing cold carrier HDL, 
immunoprecipitated with rabbit anti-apo A-I. The 
arrows indicate the electrophoretic mobility of the 
protein M, markers and the position of human plasma 
apo A-I when the gel was stained for protein. 
Analysis of [35S]methionine-labelled Hep G2 
cell-culture medium by density-gradient ultracen- 
trifugation, followed by SDS-PAGE of the frac- 
tions, revealed that only a portion of newly syn- 
thesized apo A-I was present in fractions of density 
< 1.21 g/ml, while the bulk of the labelled protein, 
including apo A-I, was in the density range 
> 1.21 g/ml, as expected for protein not bound to 
lipid (not shown). 
Protein synthesis by Hep G2 cells, measured by 
incorporation of [35S]methionine into the 10% 
(w/v) trichloroacetic acid-precipitable fraction of 
the culture medium, gradually slowed down under 
serum-free conditions, and stopped after about 
25 h (not shown). This finding permitted us to in- 
vestigate whether converting activity is associated 
with Hep G2 cells, simply by extending the incuba- 
tion period with [3’S]methionine from 8 h to 50 h. 
Fig.2, lane c, shows that prolonged incubation 
resulted in partial processing of isoform 2, in- 
dicating that Hep G2 cells produce converting 
activity. 
Isoform 4 was also produced when Hep G2 
medium was incubated with blood or plasma (con- 
taining hirudin or heparin), serum or endothelial 
cells (fig.2, lanes d-i). In all cases, processing was 
a slow process. Based on quantitation of radioac- 
tivity after isoelectrofocusing, the extent of con- 
version was about 50% after 50 h of incubation at 
37°C in the presence of 10% (v/v) hirudin-plasma. 
In contrast to hirudin- or heparin-containing 
blood or plasma, no conversion was observed with 
blood or plasma containing 2 mM EDTA (fig.2, 
lane j), which points to a metal-ion-dependent pro- 
cess. The lack of inhibition with 0.2 mM EDTA 
(fig.2, lane k) suggests that the activity is Ca*+- 
and/or Mg*+-dependent since only these cations 
occur in sufficient high concentrations in the 
media used (e.g., 0.4 mM in RPMI-1640) to escape 
complex formation with 0.2 mM EDTA. 
Incubation of Hep G2 medium with density- 
gradient fractions of serum showed that the con- 
verting activity is, at least partly, associated with 
lipoproteins (fig.2, lanes l-p). It is not clear at this 
time whether the converting activity found in the 
LPDS fraction was artificially generated during 
density-gradient ultracentrifugation or can also ex- 
ist free from lipoprotein under physiological con- 
ditions. Identical results were reported by authors 
in [ 121 who also provided evidence for lymph 
chylomicron-bound converting activity. As both 
plasma HDL and lymph chylomicrons bind pro- 
apo A-I as well, it was concluded by these authors 
that proapo A-I conversion takes place in, or on 
these lipoproteins. However, our data show that 
111 
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Fig.2. Isoelectrofocusing and autoradiography of immunoprecipitates of [“Slmethionine-labelled Hep G2 medium 
incubated with blood, plasma, serum or fractions thereof, or endothelial cells under various experimental conditions. 
Each sample was incubated with 25 ,J of radiolabelled Hep G2 medium for 50 h at 37°C. Final concentrations are given 
in parentheses. In all cases, only the area in the vicinity of the apo A-I isoproteins is shown. Lane a, gel stained for 
protein; b, 8 h of incubation of Hep G2 cells with [“Slmethionine; c, 50 h of incubation of Hep G2 cells with 
[“Slmethionine; d, hirudin blood (20%, v/v); e, heparin blood (20010); f, hirudin plasma (10%); g, heparin plasma 
(10%); h, serum (10%); i, 0.32 cm’ confluent endothelial cells; j, serum (10%) and EDTA (2 mM); k, serum (10%) 
and EDTA (0.2 mM); I, VLDL (67 pg protein/ml); m, LDL (533 pg protein/ml); n, HDLl (473 pg protein/ml); o, 
HDL3 (655 pg protein/ml); p, LPDS (32 mg protein/ml); q, endothelial cells grown under serum-free conditions; r, 
endothelial cells grown under serum-free conditions followed by 48 h of incubation with 20% (v/v) serum; s, Hep G2 
cells grown under serum-free conditions. 
cleavage of the pro-segment also occurred when 
Hep G2 medium was incubated with Hep G2 cells 
or endothelial cells (fig.2, lanes c and i, respective- 
ly), even if only a fraction of the Hep G2-secreted 
proapo A-I molecules was part of lipoprotein par- 
ticles. When the labelled Hep G2 medium was in- 
cubated with conditioned medium from Hep G2 
cells or endothelial cells no conversion was observ- 
ed (not shown), indicating that the converting ac- 
tivity expressed by these cells is cell-bound. These 
results suggest the possibility that apart from 
lipoproteins, the endothelium and hepatocytes 
may also provide a physiologically important sur- 
face for conversion of proapo A-I into the mature 
form. 
In an attempt to clarify whether the endothelial 
cell-associated converting enzyme is synthesized by 
these cells, endothelial cells were washed extensive- 
ly and, with daily renewal of the medium, were 
cultured for 50 h in M199-medium supplemented 
with 0.03% acid-treated BSA, 50pg/ml LDL, 
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100 pg/ml ECGS, 10 ng/ml EGF, 10 pug/ml in- 
sulin, 10 pg/ml human transferrin and antibiotics, 
conditions under which cell growth was maintain- 
ed [13]. At the end of the incubation period, the 
cells had lost their converting activity (fig.2, lane 
q), indicating that they do not synthesize the en- 
zyme under these conditions. Subsequent incuba- 
tion with 20% (v/v) serum for 48 h restored the 
cell-associated converting activity (fig.2, lane r), 
suggesting that the enzyme can be transferred from 
serum (lipoproteins) to the endothelial cell surface. 
Hep G2 cells were similarly treated and grown for 
50 h in M199, supplemented with 0.03% acid- 
treated BSA, 50pg/ml LDL and antibiotics, con- 
ditions under which protein synthesis was main- 
tained. In contrast to the same experiment with en- 
dothelial cells, Hep G2 cells showed no loss of con- 
verting activity (fig.2, lane s). Unless the conver- 
ting enzyme is more firmly bound to Hep G2 cells 
than to endothelial cells, this finding points to syn- 
thesis of the enzyme by Hep G2 cells. 
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In conclusion, our results show that the proapo 
A-I converting enzyme is Ca’+/Mg’+-dependent, 
is probably synthesized by Hep G2 cells, and oc- 
curs in association with the surfaces of lipoprotein 
particles, endothelial cells and Hep G2 cells. The 
functional significance of the proapo A-I-apo A-I 
system is still an open question. 
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